title: Very low-dose fluvastatin-valsartan combination decreases parameters of inflammation and oxidative stress in patients with type 1 diabetes mellitus.
abstract: OBJECTIVE
  Previously we revealed the effectiveness of a new therapeutic approach with a short-term, very-low dose fluvastatin-valsartan combination on the improvement of arterial function in type 1 diabetes mellitus patients (T1DM). In this study we explored whether this approach influences inflammation and oxidative stress and explored any association of these effects with arterial function improvement.
  
  
  METHODS
  This was a supplementary analysis of the two previous double blind randomized studies (included 44 T1DM patients). Treatment group received very-low dose fluvastatin-valsartan, the control group received placebo. Blood samples were collected and inflammation parameters: high-sensitivity CRP (hsCRP), interleukin 6 (IL-6), vascular cell adhesion molecule-1 (VCAM-1) and oxidative stress parameter total antioxidant status (TAS) were measured.
  
  
  RESULTS
  Treatment decreased hsCRP values (by 56.5%, P<0.05) and IL-6 values (by 33.6%, P<0.05) and increased TAS values (by 21.1%; P<0.05) after 30days of treatment. High sensitivity CRP and TAS remained decreased 3months after treatment discontinuation. Importantly, the anti-inflammatory and anti-oxidative action significantly correlated with arterial function improvement.
  
  
  CONCLUSIONS
  The approach consisting of short-term (30days) treatment with a very low-dose fluvastatin-valsartan combination acts anti-inflammatory and anti-oxidative in T1DM patients. These observations along with the improvement of arterial function support the assumption that this approach could have an important clinical benefit in T1DM patients.
authors.affiliation: Department of Vascular Diseases, Ljubljana University Medical Center, Zaloška cesta 7, SI-1000 Ljubljana, Slovenia; Department of Endocrinology, Diabetes and Metabolic Diseases, Ljubljana University Medical Center, Zaloška cesta 7, SI-1000 Ljubljana, Slovenia.
authors.forename: Mojca
authors.initials: M
authors.lastname: Lunder
authors.affiliation: Department of Vascular Diseases, Ljubljana University Medical Center, Zaloška cesta 7, SI-1000 Ljubljana, Slovenia.
authors.forename: Miodrag
authors.initials: M
authors.lastname: Janić
authors.affiliation: Department of Vascular Diseases, Ljubljana University Medical Center, Zaloška cesta 7, SI-1000 Ljubljana, Slovenia.
authors.forename: Vedran
authors.initials: V
authors.lastname: Savić
authors.affiliation: Department of Endocrinology, Diabetes and Metabolic Diseases, Ljubljana University Medical Center, Zaloška cesta 7, SI-1000 Ljubljana, Slovenia.
authors.forename: Andrej
authors.initials: A
authors.lastname: Janež
authors.affiliation: Diabetes & Me, Diabetes Center, Židovska cesta 1, SI-1000 Ljubljana, Slovenia.
authors.forename: Karin
authors.initials: K
authors.lastname: Kanc
authors.affiliation: Department of Vascular Diseases, Ljubljana University Medical Center, Zaloška cesta 7, SI-1000 Ljubljana, Slovenia. Electronic address: miso.sabovic@kclj.si.
authors.forename: Mišo
authors.initials: M
authors.lastname: Šabovič
mesh_terms: D000328:Adult; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D004311:Double-Blind Method; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D000077340:Fluvastatin; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007211:Indoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy*; D008297:Male; D018384:Oxidative Stress; D000068756:Valsartan / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D000077340:Fluvastatin; D000068756:Valsartan
keywords: Anti-inflammatory action; Anti-oxidative action; Diabetes mellitus type 1 patients; Fluvastatin-valsartan combination; Very low-dose